Abstract WMP1: Complications Of Intravenous Tenecteplase For The Treatment Of Acute Ischemic Stroke: A Systematic Review And Meta-Analysis

• Published in: Stroke (1970) 2023-02, Vol.54 (Suppl_1), p.AWMP1-AWMP1
• Main Authors: Rose, Deborah, Cavalier, Annie, Kam, Wayneho, Cantrell, Sarah, Lusk, Jay, Schrag, Matthew, Yaghi, Shadi, Stretz, Christoph, De Havenon, Adam H, Saldanha, Ian, Wu, Teddy Y, Ranta, Anna, Barber, Alan, Marriott, Elizabeth, Poli, Sven, Mac Grory, Brian C
• Format: Article
• Language: English
• ISSN: 0039-2499; 1524-4628
• DOI: 10.1161/str.54.suppl_1.WMP1

IntroductionPrior systematic reviews have focused on a comparison of efficacy endpoints between tenecteplase (TNK) and alteplase. The objectives of this study are to determine whether the rate of treatment complications differs between patients treated with the two agents. MethodsThis systematic review (CRD42022303835) was performed according to PRISMA guidelines. We included prospective, interventional studies and prospective and retrospective observational studies. We searched MEDLINE, the Cochrane Central Register of Controlled Trials, Embase, Web of Science and the ClinicalTrials.gov registry from inception through June 3rd 2022. The primary endpoint was symptomatic intracranial hemorrhage (sICH) and secondary endpoints included any ICH, mortality, angioedema, gastrointestinal hemorrhage and other extracranial hemorrhage. We performed separate random effects meta analyses for each endpoint. Evidence was synthesized as relative risks, comparing subjects exposed to TNK versus alteplase as well as absolute risks in those treated with TNK. ResultsOf 2,226 records identified, 26 were eligible for inclusion including 7,921 patients. Seventeen studies included alteplase as a comparator group and 10 were non-comparative. The relative risk of sICH in patients treated with TNK compared with alteplase was 0.93 (95% CI0.68-1.28). Across those treated with low, medium and high doses of TNK, the relative risks were 0.78 (95% CI0.22-2.82), 0.84 (95% CI0.58-1.20) and 2.31 (0.69-7.75) respectively. The unadjusted rate of sICH, including comparative and non-comparative studies, was 1%, 2% and 4% within the low, medium and high dose groups. DiscussionTo-date, this is the most comprehensive systematic review examining relative complications of TNK and alteplase. The rate of treatment harms is broadly comparable between those treated with the two agents. We present evidence that the rate of sICH may be increased in those treated with higher doses of TNK.